Stirling G S
Curr Med Res Opin. 1979;6(5):331-7. doi: 10.1185/03007997909109447.
An open 12-week study was carried out to investigate the use of pimozide (12 mg once daily) as a replacement for antipsychotic maintenance therapy in 30 chronic schizophrenics who had responded poorly to previous neuroleptic monotherapy or polytherapy. After 8 weeks of treatment with pimozide, all 18 symptoms of the Brief Psychiatric Rating Scale were improved from previous treatment values. These differences were statistically significant for conceptual disorganization, depressive mood, hostility and motor retardation. Eleven patients who clearly responded well during the trial and consequently continued pimozide monotherapy were judged, 1 year later, to be functioning as well, or better, than with pre-trial drug treatment.
开展了一项为期12周的开放性研究，以调查使用匹莫齐特（每日一次，12毫克）替代抗精神病维持治疗对30名慢性精神分裂症患者的效果，这些患者对之前的抗精神病药物单一疗法或联合疗法反应不佳。使用匹莫齐特治疗8周后，简明精神病评定量表的所有18项症状均较之前治疗时有所改善。这些差异在概念紊乱、抑郁情绪、敌意和运动迟缓方面具有统计学意义。在试验期间反应明显良好并因此继续接受匹莫齐特单一疗法的11名患者，在1年后被判定其功能与试验前药物治疗时相同或更佳。
